Name | N-Benzylglycylglycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-asparaginyl-L-glutamamide |
---|---|
Synonyms |
L-Glutamamide, N-(phenylmethyl)glycylglycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-asparaginyl-
N-Benzylglycylglycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-asparaginyl-L-glutamamide |
Description | UFP-101 is a potent, selective, and competitive antagonist of the nociceptin/orphanin FQ (NOP) receptor, with a pKi of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect[1][2]. |
---|---|
Related Catalog | |
In Vivo | UFP-101 elicits a pronounced acute and dosedependent antidepressant-like effect in mice submitted to the forced swimming test (FST)[1]. |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Molecular Formula | C82H138N32O21 |
Molecular Weight | 1908.175 |
Exact Mass | 1907.071411 |
LogP | -10.03 |
Index of Refraction | 1.668 |